Literature DB >> 15073093

Kinase inhibitors and cytotoxic drug resistance.

Steven Grant, Paul Dent.   

Abstract

Mesh：

Substances：

Year:  2004        PMID： 15073093     DOI： 10.1158/1078-0432.ccr-0001-4

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  11 in total

1.  Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Authors:  Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel-Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

2.  Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.

Authors:  Margaret A Park; Clint Mitchell; Guo Zhang; Adly Yacoub; Jeremy Allegood; Dieter Häussinger; Roland Reinehr; Andrew Larner; Sarah Spiegel; Paul B Fisher; Christina Voelkel-Johnson; Besim Ogretmen; Steven Grant; Paul Dent
Journal:  Cancer Res       Date:  2010-07-14       Impact factor: 12.701

3.  Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.

Authors:  Michele Navarra; Marilena Celano; Jessica Maiuolo; Silvia Schenone; Maurizio Botta; Adriano Angelucci; Placido Bramanti; Diego Russo
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

4.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.

Authors:  Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Philip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2008-10-12       Impact factor: 4.742

5.  Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

6.  Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.

Authors:  Teneille Walker; Clint Mitchell; Margaret A Park; Adly Yacoub; Martin Graf; Mohamed Rahmani; Peter J Houghton; Christina Voelkel-Johnson; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

7.  BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.

Authors:  Aditi Pandya Martin; Margaret A Park; Clint Mitchell; Teneille Walker; Mohamed Rahmani; Andrew Thorburn; Dieter Häussinger; Roland Reinehr; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2009-05-29       Impact factor: 4.436

8.  Regulation of autophagy by ceramide-CD95-PERK signaling.

Authors:  Margaret A Park; Guo Zhang; James Norris; Philip B Hylemon; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Autophagy       Date:  2008-10-05       Impact factor: 16.016

9.  OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells.

Authors:  Margaret A Park; Adly Yacoub; Mohammed Rahmani; Guo Zhang; Lori Hart; Michael P Hagan; Stuart K Calderwood; Michael Y Sherman; Costas Koumenis; Sarah Spiegel; Ching-Shih Chen; Martin Graf; David T Curiel; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2008-01-08       Impact factor: 4.436

Review 10.  Stem-like cells and therapy resistance in squamous cell carcinomas.

Authors:  Nicole Facompre; Hiroshi Nakagawa; Meenhard Herlyn; Devraj Basu
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.